The cholesterol pill Vytorin can not achieve its main objective to reduce heart diseases risks according to data released on Monday. Following this the shares of both Merck & Co Inc and Schering-Plough Corp fell down sharply. The use of drug declined as drug was not fount too reliable to cure arterial plaque.

The new study has revealed that some more incidents of cancer death were seen in people who take this drug however researchers ruled out any possibility of more deaths. 1,873 patients were tested to determine the need of surgical replacement of aortic valves, reduce cardiac death and reduce cardiovascular events. Data presented in London by its primary researcher, Dr. Terje Pedersen of Ulleval University Hospital in Oslo, Norway has revealed that result of use of placebo and Vytorin did not differ much.

Vytorin is considered better than Placebo to reduce atherosclerotic events which is called non fatal heart attack but it is not good for reducing aortic valve disease events such as surgical valve replacement and hospitalization because of heart failure and cardiovascular death.

Merck shares closed at $2.35 while Schering-Plough shares closed down11.6 percenton the New York Stock Exchange. Vytorin is jointly marketed by Merck & Co. and Schering-Plough Corp.